Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2024 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (40)	2/15/2024 12:22:19 PM
From: DewDiligence_on_SI	1 Recommendation Recommended By Arthur Radley Respond to of 195

Offerings at a premium do happen occasionally. Here’s another example from this week: investorshub.advfn.com

To: Arthur Radley who wrote (40)	2/15/2024 9:36:48 PM
From: technetium	2 Recommendations Recommended By Arthur Radley Lance Bredvold Respond to of 195

My completely uniformed opinion/wild guess is that someone knows something about how well the drug will work, or that somebody wants to buy the company outright so they can benefit from all the clinical trials that the company has done thus far. The trading volume is also very weird, per Yahoo Finance: finance.yahoo.com Average daily volume: 505,911 sh Today’s (Thursdays’) volume: 7,188,857 sh A huge spike in trading volume but perhaps the fact that they selling more stock has something to do with it, but the jump in price suggests good news in the horizon. ir.kalvista.com KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants Feb 15, 2024 CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Feb. 15, 2024-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $160.1 million. In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issuance. The purchase price of each pre-funded warrant sold in this offering will be equal to the price at which a share of common stock is sold in the offering, minus $0.001, and the exercise price of each pre-funded warrant will equal $0.001 per share. All of the shares of common stock and pre-funded warrants are being offered by KalVista. The offering is expected to close on or about February 20, 2024, subject to the satisfaction of customary closing conditions.